title: Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
abstract: Rituximab has been proven to be an important part of the treatment of newly diagnosed and relapsed or refractory follicular lymphoma both alone and in combination with chemotherapy. Given its tolerability, rituximab has now been investigated in the maintenance setting in an effort to further improve progression-free and overall survival in patients with follicular lymphoma.
authors.affiliation: Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA. rupali-roy@md.northwestern.edu
authors.forename: Rupali
authors.initials: R
authors.lastname: Roy
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab